Instructions for Ursosan Forte (Ursodeoxycholic acid) 500 mg
English product name
Release form Ursosan Forte
caps. 250 mg: 10, 50 or 100 pcs
tab, film coating, 500 mg: 10, 50 or 100 pcs
Description Ursosan Forte:
The tablets are coated with a film shell in white or almost white, are elongated and double-convex, with a groove on one side and a deep separating strip on the other side; The fracture is white or almost white.
ursodeoxycholic acid 500 mg
Auxiliary substances: cornstarch - 94.5 mg, corn starch - 48 mg, sodium carboxymethyl starch (type A) - 13 mg, silicon dioxide colloidal - 15 mg, magnesium stearate - 14.5 mg.
Opadray white 03B28796 - 5 mg (hypromellose 6 - 3.13 mg, titanium dioxide - 1.56 mg, macrogol 400 - 0.31 mg).
10 pcs - packages of box contour (1) - cardboard packs.
10 pcs - box-type contour (5) packages - cardboard packs.
10 pcs - box-type contouring packages (10) - cardboard packages.
A05AA02 Ursodeoxycholic acid
Clinical-pharmacological groups / Group affiliation
Hepatoprotector with cholelytic and cholelititic action
Pharmacotherapy group Ursosan
The tablets should be stored in a place protected from light at a temperature of 15° to 25°C.
Best before date Ursodeoxycholic acid
The shelf life is three years.
The capsules should be stored in a dry, light-proof place at a temperature of 15° to 25°C.
Do not apply after expiry date.
The drug should be stored in a place inaccessible to children.
Testimony Ursosan Forte:
- uncomplicated gallstone disease: biliary sludge;
- dissolving cholesterol gallstones in a functioning gallbladder;
- prevention of recurrence of stone formation after cholecystectomy;
- chronic hepatitis of various origins (including toxic, medicinal);
- cholestatic diseases of the liver of various origins, including primary biliary cirrhosis (in the absence of signs of
- discompensation), primary sclerosing cholangitis, cystic fibrosis (cystic fibrosis);
- non-alcoholic fatty liver disease, including non-alcoholic steatohepatitis;
- alcoholic liver disease;
- chronic viral hepatitis;
- biliary dyskinesia;
- biliary reflux gastritis and reflux esophagitis.
Method of use, course and dosage Ursosan Forte:
Take inside, during or after a meal, not chewing, drinking enough water.
To ensure the recommended dose, the tablet should be divided in half, breaking down at risk. Segments broken incorrectly should not be used. Holding a segment in the mouth tastes bitter.
For dissolving cholesterol gallstones, the average daily dose of the preparation is ten mg/kg (up to 12-15 mg/kg). Daily dose of the drug is taken once per night. The course of treatment is six to twelve months or more until the stones are completely dissolved. If gallbladder stones are not reduced in size after twelve months of treatment, the drug should be discontinued.
Application for kidney disorders
It is contraindicated in kidney failure.
Use in liver disorders
It is contraindicated in liver failure.
Terms of Sale Ursodeoxycholic acid
The drug is prescription.
- Nosology Ursosan Forte (ICD codes)
- Acute hepatitis A
- Acute hepatitis B
- Acute hepatitis C
- Chronic viral hepatitis B without delta agent
- Chronic viral hepatitis C
- Cystic fibrosis
- Gastroesophageal reflux with esophagitis
- Functional dyspepsia (digestive disorder)
- Alcoholic liver disease
- Toxic liver failure
- Fibrosis and cirrhosis
- Gallstone disease [cholelitiasis] (incl. hepatic colic)
- Other refined diseases of the gallbladder and bubble duct (including dyskinesia)
- Other specific preventive measures
Pharmacological effect Ursosan Forte:
Hepatoprotective drug. It also has cholelytic, hypolipidemic, hypocholesterolemic and immunomodulatory effects. Possessing high polar properties, ursodeoxycholic acid (UDHC) is incorporated into the hepatocyte, cholangiocyte and GI-CT epitheliocyte membrane, stabilizes its structure and protects the cell from the damaging effect of toxic bile acid salts, thereby reducing the cytotoxic effect thereof. It forms non-toxic mixed mycelles with lipophilic (toxic) bile acids, which reduces the ability of gastric reflux to damage cell membranes in cholestatic liver disease, biliary reflux gastritis, and reflux esophagitis.